Home > Research > Publications & Outputs > Subcutaneous omalizumab for people with asthma

Electronic data

  • Donovan_et_al-2021-Cochrane_Database_of_Systematic_Reviews

    Rights statement: This is the version of record of the following protocol: Donovan T, Milan SJ, Adatia A, Solkar Z, Stovold E, Dwan K, Hinks TSC, Crossingham I. Subcutaneous omalizumab for people with asthma. Cochrane Database of Systematic Reviews 2021, Issue 7. Art. No.: CD014975. DOI: 10.1002/14651858.CD014975. Accessed 19 August 2021 which has been published in final form at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014975/full This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.

    Final published version, 147 KB, PDF document

    Embargo ends: 22/07/22

    Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License

Links

Text available via DOI:

View graph of relations

Subcutaneous omalizumab for people with asthma

Research output: Contribution to journalJournal articlepeer-review

Published
Close
<mark>Journal publication date</mark>22/07/2021
<mark>Journal</mark>Cochrane Database of Systematic Reviews
Issue number7
Volume2021
Number of pages11
Publication StatusPublished
<mark>Original language</mark>English

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To evaluate the effects of subcutaneous omalizumab versus placebo for asthma in adults and children. 

Bibliographic note

This is the version of record of the following protocol: Donovan T, Milan SJ, Adatia A, Solkar Z, Stovold E, Dwan K, Hinks TSC, Crossingham I. Subcutaneous omalizumab for people with asthma. Cochrane Database of Systematic Reviews 2021, Issue 7. Art. No.: CD014975. DOI: 10.1002/14651858.CD014975. Accessed 19 August 2021 which has been published in final form at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014975/full This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.